Zacks Investment Research lowered shares of Mast Therapeutics, Inc. (NASDAQ:SVRA) from a buy rating to a hold rating in a report released on Thursday.
According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “
Separately, Canaccord Genuity reiterated a buy rating and set a $18.00 target price on shares of Mast Therapeutics in a research note on Monday, July 17th.
Mast Therapeutics (NASDAQ SVRA) opened at 6.80 on Thursday. The stock has a 50 day moving average of $5.72 and a 200 day moving average of $5.88. Mast Therapeutics has a 12-month low of $4.60 and a 12-month high of $45.35. The firm’s market capitalization is $164.58 million.
COPYRIGHT VIOLATION WARNING: “Mast Therapeutics, Inc. (SVRA) Rating Lowered to Hold at Zacks Investment Research” was reported by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/09/11/mast-therapeutics-inc-svra-rating-lowered-to-hold-at-zacks-investment-research.html.
About Mast Therapeutics
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.